

心理的介入はがん再発の恐怖を軽減する (Abstract LBS10000)

心理的介入はリラクゼーショントレーニングよりも、がん既往者の再発に対する恐怖を緩和する

Psychological intervention relieves cancer survivors fear of recurrence better than relaxation training

すべてのがん患者の約50%および若年乳がん既往者の約70%が、中等度から重度の再発の恐怖を報告している。第II相ランダム化臨床試験において、研究者らは、再発の恐怖が重度であると報告したステージI-IIIの乳がん、大腸がん、または悪性黒色腫の既往者222人を、Conquer Fear 心理的介入またはリラクゼーショントレーニング(コントロール群)にランダムに割り付けた。その結果、Conquer Fear は介入直後、3か月後および6か月後の再発の恐怖を大幅に軽減した。全般的な不安障害、がん特異的苦悩、およびQOLは心理的介入群がリラクゼーショントレーニングよりも優れていた。このスタディ結果は2017年 American Society of Clinical Oncology 年次集会で取り上げられた。

Full Text

About 50% of all cancer survivors and 70% of young breast cancer survivors report moderate to high fear of recurrence. The fear can be so distressing that it negatively affects medical follow-up behavior, mood, relationships, work, goal setting, and quality of life. Yet, interventions to alleviate this fear are lacking.

In a phase II randomized clinical trial, a psychological intervention called Conquer Fear substantially lowered fear of recurrence immediately after the intervention, and three and six months later. General anxiety, cancer-specific distress, and quality of life were better in the psychological intervention group immediately after therapy.

The study was featured at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.

"The reduction in fear of recurrence in the psychological intervention group was large enough to improve survivors' psychological and emotional wellbeing," said lead study author Jane Beith, MD, PhD, a Medical Oncologist at the University of Sydney in Australia, who developed the Conquer Fear intervention with colleagues, including psycho-oncologist Phyllis Butow, BA(Hons) Dip Ed, MClinPsych, MPH, PhD. "The majority of participants were young women with breast cancer, but we expect the intervention may be appropriate for other patients who have moderate to high fear of recurrence."

The Conquer Fear psychology intervention is based on a novel theoretical framework developed by the authors (the intervention was developed for research and is not yet used in clinical practice). Trained study therapists delivered the intervention in five 60- to 90-minute individual, face-to-face sessions over 10 weeks. Conquer Fear focuses on:

- Accepting the inherent uncertainty of whether the cancer would come back
- Teaching strategies to control worry
- Giving survivors more control over where they place their attention
- Helping them focus on what they want to get out of life
- Choosing a sensible level of cancer screening and sticking to it

Researchers randomly assigned 222 survivors of stage I-III breast cancer, colorectal cancer, or melanoma who reported high fear of recurrence to either the Conquer Fear intervention or relaxation training (control group). All survivors had completed cancer treatment two months to five years before enrolling in this study and were cancer free at the time.

Survivors in the control group received five 60-minute, individual, face-to-face relaxation sessions. The sessions were delivered over 10 weeks by trained study therapists and incorporated muscle relaxation, meditative relaxation, and visualization and quick relaxation techniques. Both groups received instructions for home-based practice.

To measure change in fear of cancer recurrence, researchers used total scores from a validated 42-item questionnaire called Fear of Cancer Recurrence Inventory or FCRI. The scores range from 0 to 168, with higher scores indicating worse fear of recurrence. Survivors completed the questionnaire at enrollment, immediately after the intervention, and three and six months later.

The average FCRI score at baseline was 82.7 in the intervention arm and 85.7 in the control arm. The primary outcome of the study, total fear-of-cancer-recurrence score, was reduced significantly more in the intervention group (by 18.1 points on average) than in the control group (by 7.6 points on average), immediately after the intervention. This represents a standardized effect size of 0.44, within the range considered clinically important.

FCRI scores continued to decrease over time, with significant difference between groups at 6 months, decreasing by 27.2 points on average in the intervention group and 17.8 points on average in the control group.

The researchers also explored other patient outcomes, including cancer-specific distress (how much someone is plagued with thoughts about cancer), general distress (anxiety, depression, and stress), and quality of life (covers independent living, physical pain, mental health, happiness, coping, relationships, and self-worth). The psychological intervention had a greater positive effect on these outcomes than relaxation training.

"The number of people surviving cancer is higher than ever before, but many survivors fear that the cancer will return even long after they have finished treatment. The hope is that the positive results of this fear-reducing intervention will pave the way for making it more widely available to patients," said Don S. Dizon, MD, FACP, ASCO Expert.

The authors note that while Conquer Fear is effective in a face-to-face format, it is a time- and resource-intensive intervention. Other formats, such as delivery via internet, in a group, or by phone, may be possible. A stepped care approach could also be considered, with only those with severe fear of recurrence receiving face-to-face intervention.

"In this study, the interventions were delivered by experienced psycho-oncologists. It is possible that community psychologists or other professionals who have basic training in cognitive therapy could deliver the interventions, given appropriate training and supervision," said Dr. Beith.

This study was funded by Cancer Australia, beyond blue and National Breast Cancer Foundation.

ASCO2017特集

[News 01]

ナッツの摂取が大腸がん再発リスクを低下させる

[News 02]

胆管がん患者の生存期間延長

[News 03]

分子標的治療は肺がんの再発を遅延させる

[News 04]

結腸がん治療後の健康的なライフスタイルは生存率を改善する

[News 05]

ワクチン使用による経口HPV感染の軽減

[News 06]

結腸がんに対する補助療法の改善

[News 07]

症状を自己報告するウェブベースのシステムは患者の生存期間延長に役立つ

[News 08]

OlaparibはBRCA関連転移性乳がんの増殖を遅延させる

[News 09]

多発性骨髄腫に対する新たなタイプの免疫療法

[News 10]

EGFR遺伝子変異陽性肺がんの新たな治療の可能性

[News 11]

アレクチニブは肺がんの無増悪生存期間を改善する

[News 12]

浸潤性乳がんのリスクを低下させる

[News 13]

新規診断転移性前立腺がんにおける予後の改善

[News 14]

Larotrectinibは多様な腫瘍タイプに効果的である

[News 15]

短期および長期の放射線治療は患者の可動性を維持するのに役立つ

[News 16]

胸膜中皮腫に対する初めての免疫療法の兆しが見える

[News 17]

心理的介入はがん患者の苦悩を緩和する

[News 18]

乳がん罹患後の妊娠は再発率を上昇させない

[News 19]

精巣腫瘍による性腺機能低下症は慢性的な健康問題と関連がある

[News 20]

心理的介入はがん再発の恐怖を軽減する